Mary has held a range of senior leadership roles in the pharmaceutical industry for more than 25 years. Before joining the biotech community she was Senior Vice President and Global Franchise Leader at GSK responsible for the Immuno-inflammation and Infectious Diseases franchise. Mary is a non-executive independent director at Galapagos NV.
Mary has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. She was a founding member of the executive team of ViiV Healthcare (the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc. and Shionogi) where she led, revitalised and grew the business in Europe. Mary also established and built the European Critical Disease Business in GSK Mary gained a PhD in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation, Detroit and has an MBA from the University of Kingston.